Budget Impact of the Introduction of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir, the First Integrase Inhibitor-Based Single Tablet Antiretroviral Regimen for Hiv Treatment, to Third Party Payers in the United States

Brogan, A., Talbird, S., Thompson, JR., Kim, YA., Olson, J., Peterson, J., Piontkowsky, D., & Pietrandoni, G. (2013). Budget Impact of the Introduction of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir, the First Integrase Inhibitor-Based Single Tablet Antiretroviral Regimen for Hiv Treatment, to Third Party Payers in the United States. Value in Health, 16(7), A343-A344.

Publications Info

To contact an RTI author, request a report, or for additional information about publications by our experts, send us your request.

Recent Publications

Article

Multifaceted risk for non-suicidal self-injury only versus suicide attempt in a population-based cohort of adults
Article

Pregnancy rates and clinical outcomes among women living with HIV enrolled in HPTN 052
Article

The influence of mediators on the relationship between antenatal opioid agonist exposure and the severity of neonatal opioid withdrawal syndrome
Article

A scoping review of empirical research on prescription drug promotion